Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
Posted on: Tuesday, 20 October 2009, 08:15 CDT
"The selection of Oramed as one of the companies to present at the
Diabetes Technology Conference is a wonderful opportunity for us to
demonstrate our technology to the world's leading diabetes scientists," said
Oramed's abstract will be presented on
For more information about the Diabetes Technology Society's Ninth Annual Meeting, please visit http://www.diabetestechnology.org/
For more information about Oramed Pharmaceuticals, please visit http://www.oramed.com
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Company Contact: Oramed Pharmaceuticals Tara Horn Cell: +972-54-334-318 Office: +972-2-566-0001 Email: tara@oramed.comSOURCE Oramed Pharmaceuticals Inc.
Source: PR Newswire
Related Articles
- Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting
- Oramed Pharmaceuticals Presents Results of Oral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs
- Bradley Pharmaceuticals Skin Cancer Screening Tour Encourages Visits to Dermatologists
- Bradley Pharmaceuticals 2006 Results
- Skystar Bio-Pharmaceutical Signs Agreement With TNI-Penta for Research and Development of New Veterinary Drugs
- WunderMarx Launches Web Site for UC Irvine Center for Diabetes Treatment and Research
- Palatin Technologies and King Pharmaceuticals Report Results For Two Phase 2B Clinical Trials Evaluating Bremelanotide in Male Erectile Dysfunction Patients
- Sirtris Pharmaceuticals Hires Mike Jirousek As SVP of Research
- Memory Pharmaceuticals Announces Agreement With the Stanley Medical Research Institute for the Development of MEM 1003 for Bipolar Disorder
- OSI Pharmaceuticals Summarizes Pre-Clinical Data From Its Research & Development Program Presented at the 96th Annual Meeting of the American Association for Cancer Research
 |
 |
User Comments (0)
RSS Feeds